CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 188 enrolled
Drug / intervention
Refresh Optive® Gel Drops +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02280473
NCT02280473Phase 3Completed

A Safety and Efficacy Study of Refresh Optive® Gel Drops in Patients With Dry Eye Disease

Allergan·interventional·Posted Oct 31, 2014·Updated Apr 16, 2019

In Brief

A Phase 3 clinical trial evaluating Refresh Optive® Gel Drops and REFRESH LIQUIGEL® for Dry Eye Syndromes. Completed, enrolled 188 participants across 10 sites.

Detailed Summary

This study will evaluate the safety and efficacy o fRefresh Optive® Gel Drops in patients with dry eye disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 31, 2014
Enrollment StartNov 13, 2014
Primary CompletionMar 16, 2015
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 11.7 years ago

Interventions

Refresh Optive® Gel Dropsdrug

Refresh Optive® Gel Drops; 1-2 drops in each eye as needed at least 2 times daily for 30 days.

REFRESH LIQUIGEL®drug

REFRESH LIQUIGEL®; 1-2 drops in each eye as needed at least 2 times daily for 30 days.